It's diagnostics, stupid
- PMID: 20371338
- DOI: 10.1016/j.cell.2010.03.018
It's diagnostics, stupid
Abstract
To stem the spiraling cost of cancer treatment, a concerted effort is urgently needed to develop molecular diagnostics to better identify the patients that respond to expensive targeted therapies. Opportunities and obstacles in the development of such drug response biomarkers are discussed here.
Copyright 2010 Elsevier Inc. All rights reserved.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
